Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

Siren said proceeds will go toward investigational new drug (IND)-enabling animal studies and clinical-grade production of therapy. Upon FDA approval of an IND application, Siren plans to start on ...

OXB Named Among UK’s Best Employers by Financial Times in 2025Oxford, UK – OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, has been honoured with a spot on the ...

D Molecular Therapeutics, Inc.’s FDMT share price has surged by 5.88%, which has investors questioning if this is right time ...

The Viral Vector & Plasmid DNA Manufacturing Market Size accounted for USD 5.4 Billion in 2023 and is estimated to achieve a ...

Report Ocean’s latest analysis delves into the “Vietnam Viral Vector and Plasmid DNA Manufacturing Market” Report from 2024 to 2032, covering an array of market facets such as characteristics, size, ...

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over China. | A special congressional committee has recommended a $15 billion ...

Belief BioMed (BBM) and Takeda China have announced China’s National Medical Products Administration's (NMPA) approval for ...

This is the first hemophilia B gene therapy drug and the first recombinant adeno-associated virus (rAAV) vector gene therapy drug developed and manufactured in Asia, marking a new milestone in China's ...

Clinical Infectious Diseases has launched a new series that will provide an in-depth look at real-life complex cases and the associated diagnostic ... by increased HIV viral load and decreased ...